Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion session - NETs and endocrine tumours

2643 - Synergistic anti-cancer activity of tyrosine kinase inhibitors and paclitaxel with radiation on anaplastic thyroid cancer in vitro and in vivo


22 Oct 2018


Poster Discussion session - NETs and endocrine tumours


Cytotoxic Therapy;  Translational Research;  Radiation Oncology

Tumour Site

Thyroid Cancer


Yong Sang Lee


Annals of Oncology (2018) 29 (suppl_8): viii645-viii648. 10.1093/annonc/mdy302


Y.S. Lee, H. Chang, S.Y. Kim, H. Chang, C.S. Park

Author affiliations

  • Thyroid Cancer Center, Department Of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, 06219 - seoul/KR


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2643


Anaplastic thyroid carcinoma (ATC) although rare is the most deadly form of thyroid cancer. The goal of this study was to investigate the anti-tumor activities of paclitaxel with radiation and in combination with tyrosine kinase inhibitors (TKI) in anaplastic thyroid cancer cells in vitro and in vivo.


Three ATC cell lines were exposed to TKI in the presence or absence of paclitaxel with radiation and cell viability was determined by MTT assay. Effects of combined treatment on cell cycle and intracellular signaling pathways were assessed by flow cytometry and western blot analysis. The ATC cell lines xenograft model was used to examine the anti-tumor activity in vivo.


Our data showed that paclitaxel with radiation and TKIs synergistically decreased cell viability in ATC cells, and also significantly increased apoptotic cell death in these cells, as proved by the cleavage of caspase-3 and DNA fragmentation. Paclitaxel and TKI with radiation combination reduced anti-apoptotic factor in ATC. Thus, TKI that targeted the vascular endothelial growth factor receptor family (VEGFR-2 and -3) and platelet-derived growth factor receptor family (PDGFR-beta and Kit), which play key roles in tumor progression and angiogenesis. Combination therapy with paclitaxel and TKI with radiation significantly decreased vessel density, and most significantly reduced tumor volume and increased survival in ATC xenografts.


These results propose that paclitaxel and TKI with radiation has significant anti-cancer activity in preclinical models, potentially suggesting a new clinical approach for patients of advanced thyroid cancer type.

Clinical trial identification

Legal entity responsible for the study

Yong Sang Lee.


Has not received any funding.

Editorial Acknowledgement


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.